Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Assessment of duration of action, safety & toleration of different formulations and doses of
UK-369,003 and Cialis in patients with male erectile dysfunction. Patients should have
previously been on PDE5 inhibitors and have been respondents to the drug. Duration of
treatment is 4 weeks.